Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.94
BMY's Cash to Debt is ranked higher than
67% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. BMY: 0.94 )
BMY' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.94

Equity to Asset 0.45
BMY's Equity to Asset is ranked higher than
57% of the 822 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. BMY: 0.45 )
BMY' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.55
Current: 0.45

0.33
0.55
Interest Coverage 15.56
BMY's Interest Coverage is ranked higher than
60% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.76 vs. BMY: 15.56 )
BMY' s 10-Year Interest Coverage Range
Min: 4.67   Max: 50.72
Current: 15.56

4.67
50.72
F-Score: 5
Z-Score: 5.71
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.07
BMY's Operating margin (%) is ranked higher than
86% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. BMY: 17.07 )
BMY' s 10-Year Operating margin (%) Range
Min: 10.45   Max: 31.04
Current: 17.07

10.45
31.04
Net-margin (%) 16.92
BMY's Net-margin (%) is ranked higher than
90% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. BMY: 16.92 )
BMY' s 10-Year Net-margin (%) Range
Min: 9.19   Max: 56.42
Current: 16.92

9.19
56.42
ROE (%) 17.92
BMY's ROE (%) is ranked higher than
92% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.98 vs. BMY: 17.92 )
BMY' s 10-Year ROE (%) Range
Min: 13.25   Max: 78.36
Current: 17.92

13.25
78.36
ROA (%) 7.73
BMY's ROA (%) is ranked higher than
85% of the 913 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.21 vs. BMY: 7.73 )
BMY' s 10-Year ROA (%) Range
Min: 5.69   Max: 35.08
Current: 7.73

5.69
35.08
ROC (Joel Greenblatt) (%) 53.24
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.70 vs. BMY: 53.24 )
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 36.14   Max: 147.49
Current: 53.24

36.14
147.49
Revenue Growth (%) -4.40
BMY's Revenue Growth (%) is ranked higher than
59% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. BMY: -4.40 )
BMY' s 10-Year Revenue Growth (%) Range
Min: -4.4   Max: 11.8
Current: -4.4

-4.4
11.8
EBITDA Growth (%) -16.80
BMY's EBITDA Growth (%) is ranked higher than
57% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. BMY: -16.80 )
BMY' s 10-Year EBITDA Growth (%) Range
Min: -16.8   Max: 21.5
Current: -16.8

-16.8
21.5
EPS Growth (%) -5.10
BMY's EPS Growth (%) is ranked higher than
67% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. BMY: -5.10 )
BMY' s 10-Year EPS Growth (%) Range
Min: -22.9   Max: 30.7
Current: -5.1

-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BMY Guru Trades in Q4 2013

Stanley Druckenmiller 954,200 sh (New)
Joel Greenblatt 11,679 sh (New)
Ken Fisher 18,138 sh (+13.81%)
Jeremy Grantham 8,939,857 sh (+6.82%)
Murray Stahl 62,672 sh (+3.47%)
Pioneer Investments 86,808 sh (+1.53%)
Jeff Auxier 5,782 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Vanguard Health Care Fund 24,459,861 sh (unchged)
George Soros 100,000 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Dodge & Cox 79,921 sh (-0.25%)
Bill Frels 300,756 sh (-1.38%)
Irving Kahn 27,650 sh (-2.3%)
Mario Gabelli 730,771 sh (-5.08%)
Manning & Napier Advisors, Inc 241,961 sh (-9.19%)
Paul Tudor Jones 100,000 sh (-55.56%)
Steven Cohen 630,599 sh (-65.77%)
Jim Simons 41,200 sh (-99.05%)
» More
Q1 2014

BMY Guru Trades in Q1 2014

Ronald Muhlenkamp 212,015 sh (New)
Ray Dalio 4,428 sh (New)
Jim Simons 1,491,855 sh (+3521.01%)
Steven Cohen 1,821,145 sh (+188.8%)
Vanguard Health Care Fund 29,437,761 sh (+20.35%)
Irving Kahn 29,650 sh (+7.23%)
Jeff Auxier 5,782 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Murray Stahl 62,672 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
George Soros Sold Out
Dodge & Cox 79,121 sh (-1%)
Bill Frels 296,839 sh (-1.3%)
Pioneer Investments 84,846 sh (-2.26%)
Mario Gabelli 686,785 sh (-6.02%)
Ken Fisher 15,733 sh (-13.26%)
Manning & Napier Advisors, Inc 206,869 sh (-14.5%)
Jeremy Grantham 4,144,419 sh (-53.64%)
Paul Tudor Jones 16,349 sh (-83.65%)
» More
Q2 2014

BMY Guru Trades in Q2 2014

Joel Greenblatt 89,363 sh (New)
Ken Fisher 49,732 sh (+216.1%)
Paul Tudor Jones 34,712 sh (+112.32%)
Jim Simons 2,459,200 sh (+64.84%)
Vanguard Health Care Fund 36,197,961 sh (+22.96%)
Brian Rogers 6,064,800 sh (+3.41%)
Pioneer Investments 85,646 sh (+0.94%)
Murray Stahl 62,972 sh (+0.48%)
Ronald Muhlenkamp 212,770 sh (+0.36%)
Steven Cohen 3,900 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc Sold Out
Dodge & Cox 78,921 sh (-0.25%)
Bill Frels 293,539 sh (-1.11%)
Mario Gabelli 674,685 sh (-1.76%)
Irving Kahn 27,650 sh (-6.75%)
Jean-Marie Eveillard 14,492 sh (-12.28%)
Jeff Auxier 5,043 sh (-12.78%)
Jeremy Grantham 1,821,771 sh (-56.04%)
» More
Q3 2014

BMY Guru Trades in Q3 2014

Ray Dalio 10,228 sh (New)
Dodge & Cox 90,428 sh (+14.58%)
Vanguard Health Care Fund 38,480,761 sh (+6.31%)
Mario Gabelli 700,255 sh (+3.79%)
Brian Rogers 6,264,800 sh (+3.3%)
Ken Fisher 51,201 sh (+2.95%)
Bill Frels 294,435 sh (+0.31%)
Jeff Auxier 5,043 sh (unchged)
Irving Kahn 27,650 sh (unchged)
Jean-Marie Eveillard 14,492 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Murray Stahl 62,942 sh (-0.05%)
Ronald Muhlenkamp 212,485 sh (-0.13%)
Pioneer Investments 84,994 sh (-0.76%)
Jeremy Grantham 1,520,723 sh (-16.53%)
Paul Tudor Jones 14,869 sh (-57.16%)
Jim Simons 270,900 sh (-88.98%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Add 6.31%0.3%$47.86 - $51.96 $ 60.7922%38480761
Joel Greenblatt 2014-09-30 Sold Out 0.05%$47.86 - $51.96 $ 60.7922%0
Ray Dalio 2014-09-30 New Buy$47.86 - $51.96 $ 60.7922%10228
Vanguard Health Care Fund 2014-06-30 Add 22.96%0.86%$46.59 - $52.19 $ 60.7923%36197961
Joel Greenblatt 2014-06-30 New Buy0.05%$46.59 - $52.19 $ 60.7923%89363
Ray Dalio 2014-06-30 Sold Out $46.59 - $52.19 $ 60.7923%0
Ken Fisher 2014-06-30 Add 216.1%$46.59 - $52.19 $ 60.7923%49732
Ronald Muhlenkamp 2014-03-31 New Buy1.9%$48.54 - $56.61 $ 60.7914%212015
Vanguard Health Care Fund 2014-03-31 Add 20.35%0.73%$48.54 - $56.61 $ 60.7914%29437761
George Soros 2014-03-31 Sold Out 0.05%$48.54 - $56.61 $ 60.7914%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$48.54 - $56.61 $ 60.7914%0
Ray Dalio 2014-03-31 New Buy$48.54 - $56.61 $ 60.7914%4428
Joel Greenblatt 2013-12-31 New Buy0.02%$46.41 - $53.84 $ 60.7919%11679
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP980.150.20$2.00 Convertible Preferred Stock

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.50
BMY's P/E(ttm) is ranked higher than
78% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.60 vs. BMY: 37.50 )
BMY' s 10-Year P/E(ttm) Range
Min: 4.05   Max: 58.14
Current: 37.5

4.05
58.14
P/B 6.60
BMY's P/B is ranked higher than
58% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. BMY: 6.60 )
BMY' s 10-Year P/B Range
Min: 2.46   Max: 6.64
Current: 6.6

2.46
6.64
P/S 6.30
BMY's P/S is ranked higher than
64% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. BMY: 6.30 )
BMY' s 10-Year P/S Range
Min: 1.63   Max: 6.3
Current: 6.3

1.63
6.3
PFCF 29.20
BMY's PFCF is ranked higher than
90% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BMY: 29.20 )
BMY' s 10-Year PFCF Range
Min: 7.44   Max: 141.78
Current: 29.2

7.44
141.78
EV-to-EBIT 36.71
BMY's EV-to-EBIT is ranked higher than
76% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.43 vs. BMY: 36.71 )
BMY' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 179.4
Current: 36.71

6.6
179.4
Shiller P/E 24.70
BMY's Shiller P/E is ranked higher than
89% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.36 vs. BMY: 24.70 )
BMY' s 10-Year Shiller P/E Range
Min: 10.15   Max: 24.76
Current: 24.7

10.15
24.76
Current Ratio 1.75
BMY's Current Ratio is ranked higher than
62% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. BMY: 1.75 )
BMY' s 10-Year Current Ratio Range
Min: 1.13   Max: 2.32
Current: 1.75

1.13
2.32
Quick Ratio 1.56
BMY's Quick Ratio is ranked higher than
67% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BMY: 1.56 )
BMY' s 10-Year Quick Ratio Range
Min: 0.93   Max: 2.06
Current: 1.56

0.93
2.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.40
BMY's Dividend Yield is ranked higher than
78% of the 519 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. BMY: 2.40 )
BMY' s 10-Year Dividend Yield Range
Min: 2.37   Max: 7.07
Current: 2.4

2.37
7.07
Dividend Payout 0.88
BMY's Dividend Payout is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BMY: 0.88 )
BMY' s 10-Year Dividend Payout Range
Min: 0.08   Max: 4
Current: 0.88

0.08
4
Dividend growth (3y) 3.00
BMY's Dividend growth (3y) is ranked higher than
78% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BMY: 3.00 )
BMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 11.4
Current: 3

0
11.4
Yield on cost (5-Year) 2.80
BMY's Yield on cost (5-Year) is ranked higher than
78% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. BMY: 2.80 )
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.76   Max: 8.24
Current: 2.8

2.76
8.24
Share Buyback Rate 1.30
BMY's Share Buyback Rate is ranked higher than
89% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. BMY: 1.30 )
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -0.3
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.80
BMY's Price/Tangible Book is ranked higher than
57% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.32 vs. BMY: 15.80 )
BMY' s 10-Year Price/Tangible Book Range
Min: 4.91   Max: 53.3
Current: 15.8

4.91
53.3
Price/DCF (Projected) 2.00
BMY's Price/DCF (Projected) is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. BMY: 2.00 )
BMY' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 4.53
Current: 2

1.13
4.53
Price/Median PS Value 2.40
BMY's Price/Median PS Value is ranked higher than
58% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. BMY: 2.40 )
BMY' s 10-Year Price/Median PS Value Range
Min: 0.73   Max: 3.24
Current: 2.4

0.73
3.24
Price/Graham Number 5.10
BMY's Price/Graham Number is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.17 vs. BMY: 5.10 )
BMY' s 10-Year Price/Graham Number Range
Min: 1.39   Max: 7.03
Current: 5.1

1.39
7.03
Earnings Yield (Greenblatt) 2.70
BMY's Earnings Yield (Greenblatt) is ranked higher than
75% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 2.70 )
BMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 15.2
Current: 2.7

0.6
15.2
Forward Rate of Return (Yacktman) -12.27
BMY's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.85 vs. BMY: -12.27 )
BMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.3   Max: 27.4
Current: -12.27

-12.3
27.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BRM.Germany, BMYMP.USA, BMYB34.Brazil, BMY.Mexico, BMY.Argentina,
Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called 'biologics'. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mechanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's key products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company Oct 19 2014 
The Six Types of Winning Stocks Oct 17 2014 
Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 


More From Other Websites
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 Dec 17 2014
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 Dec 17 2014
Jim Cramer: These Charts Prove It's Oil-and-Gas vs. Everything Else Dec 16 2014
Celgene's Abraxane Succeeds In Early Breast Cancer Dec 11 2014
Gilead Is Growing Fast And Its Stock Is Cheap Dec 11 2014
Merck's Keytruda Might Treat Virulent Breast Cancer Dec 10 2014
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical... Dec 10 2014
Bristol-Myers Squibb Announces Dividend Dec 09 2014
Bristol-Myers Squibb Announces Dividend Dec 09 2014
US sues Deutsche in $190m taxes claim Dec 08 2014
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data Dec 08 2014
Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex... Dec 08 2014
Two Cancer Drugs for Hodgkin Lymphoma Shown Effective Dec 08 2014
What’s News: Business & Finance Dec 08 2014
Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex... Dec 08 2014
Asia Corporate Watch Dec 07 2014
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or... Dec 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK